Dopaminergic enhancement of cognitive function

被引:68
作者
Mehta, Mitul A.
Riedel, Wim J.
机构
[1] Kings Coll London, Ctr Neuroimaging Sci, Inst Psychiat, London SE5 8AF, England
[2] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC Ctr Clin Sci, PET Psychiat Grp, London SW7 2AZ, England
[3] GlaxoSmithKline, Clin Pharmacol & Discovery Med, Cambridge, England
[4] Univ Maastricht, Fac Psychol, Dept Neurocognit, Maastricht, Netherlands
[5] Univ Cambridge, Dept Psychiat, Cambridge CB2 1TN, England
关键词
D O I
10.2174/138161206777698891
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ascending dopamine system of the mammalian brain has been associated with motor, mnemonic and goal-directed or reward-related behaviour. The most progress in understanding the cortical mechanisms of dopaminergic modulation of function has been made with regards to short-term mnemonic (or working memory) function. Research in experimental animals strongly suggests that stimulation of dopamine D1 receptors in the prefrontal cortex can ameliorate spatial working memory related cognitive deficits, and may even enhance cognitive function in healthy animals. Research in humans has not been able to clearly replicate these findings, partly due to the lack of available agents that can safely be used. Low doses of dopamine D2 receptor agonists such as bromocriptine and pergolide may be able to enhance working memory and executive functions, but these effects may be dependent on the nature of the tasks used and the baseline performance levels of the subjects. Thus, the effects of dopaminergic cognitive enhancers may not be simple, or uniform across subjects. Systematic studies in humans carefully controlling task parameters are needed in order to specify the potential cognitive processes open to enhancement with dopaminergics. However, since the DA receptor subtypes in different brain regions appear to differentially influence similar functions, carefully defining the cognitive processes to be tested against potential therapeutics is an equally important goal. Studies in patients groups using selective dopaminergics are rather restricted, but show promise for designing large-scale clinical trials into the cognitive enhancing properties of potential therapeutic agents that act through the dopamine system.
引用
收藏
页码:2487 / 2500
页数:14
相关论文
共 164 条
[1]   Prefrontal dopamine D1 receptors and working memory in schizophrenia [J].
Abi-Dargham, A ;
Mawlawi, O ;
Lombardo, I ;
Gil, R ;
Martinez, D ;
Huang, YY ;
Hwang, DR ;
Keilp, J ;
Kochan, L ;
Van Heertum, R ;
Gorman, JM ;
Laruelle, M .
JOURNAL OF NEUROSCIENCE, 2002, 22 (09) :3708-3719
[2]   Do we still believe in the dopamine hypothesis? New data bring new evidence [J].
Abi-Dargham, A .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 :S1-S5
[3]   EFFECTS OF DOPAMINERGIC AGENTS ON MONOAMINE LEVELS AND MOTOR BEHAVIOR IN PLANARIA [J].
ALGERI, S ;
CAROLEI, A ;
FERRETTI, P ;
GALLONE, C ;
PALLADINI, G ;
VENTURINI, G .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-PHARMACOLOGY TOXICOLOGY & ENDOCRINOLOGY, 1983, 74 (01) :27-29
[4]  
Altieri M, 2002, STROKE, V33, P1170, DOI 10.1161/01.STR.0000012265.78381.ED
[5]   DOPAMINE RECEPTOR SUBTYPES - BEYOND THE D1/D2 CLASSIFICATION [J].
ANDERSEN, PH ;
GINGRICH, JA ;
BATES, MD ;
DEARRY, A ;
FALARDEAU, P ;
SENOGLES, SE ;
CARON, MG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (06) :231-236
[6]  
[Anonymous], 1997, The dopamine receptors
[7]  
ARNSTEN AFT, 1995, J NEUROSCI, V15, P3429
[8]   The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys [J].
Arnsten, AFT ;
Murphy, B ;
Merchant, K .
NEUROPSYCHOPHARMACOLOGY, 2000, 23 (04) :405-410
[9]   Noise stress impairs prefrontal cortical cognitive function in monkeys - Evidence for a hyperdopaminergic mechanism [J].
Arnsten, AFT ;
Goldman-Rakic, PS .
ARCHIVES OF GENERAL PSYCHIATRY, 1998, 55 (04) :362-368
[10]   Catecholamine regulation of the prefrontal cortex [J].
Arnsten, AFT .
JOURNAL OF PSYCHOPHARMACOLOGY, 1997, 11 (02) :151-162